Timothy D. Clay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Timothy D. Clay has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
Bryan M. Clary
6 shared publications- David S. Hsu
Department of Medicine, Division of Medical Oncology, Duke University Medical Center , Durham, NC
6 shared publications H. Kim Lyerly
6 shared publications- Jennifer A. Freedman
Division of Medical Oncology, Department of Medicine Duke University School of Medicine Durham North Carolina USA
6 shared publications Katherine A. Tsamis
6 shared publications- Michael A. Morse
Ascension Saint Thomas, Nashville, TN (M.A.M.M., E.R.).
6 shared publications
Latest Publications
- Open Access
- 4 March 2026
- Published by Taylor & Francis in Future Oncology
- Vol. 22 (7) , 795-803
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2 -mutant solid tumors
1. Human epidermal growth factor receptor 2 (HER2, encoded by the ERBB2 gene), a member of the ErbB family of receptors, may be altered (overexpressed, amplified or mutated) in many different types...
- 4 March 2026
- Published by Taylor & Francis in Future Oncology
- Vol. 22 (7) , 795-803
Open AccessBeamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2 -mutant solid tumors
1. Human epidermal growth factor receptor 2 (HER2, encoded by the ERBB2 gene), a member of the ErbB family of receptors, may be altered (overexpressed, amplified or mutated) in many different types...
- Open Access
- 27 February 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (3) , 257
Clinical insights into the management of sleep disturbances within cancer care: a qualitative analysis
Purpose: The present study aimed to gain a deeper understanding of how oncology healthcare professionals’ (HCPs) manage sleep disturbances. Methods: Semi-structured interviews were conducted with 10 oncology HCPs (medical oncologists, oncology nurse practitioners, clinical nurse consultants) working in metropolitan Perth, Western Australia. Reflexive thematic analysis was used to understand oncology HCPs’ perspectives on treating sleep disturbances, explore challenges and barriers to their management, as well as opportunities for improvement. Results: Four main themes were developed: (1) sleep disturbances are underreported and underassessed, (2) poor sleep can be difficult to manage, (3) limited capacity to address sleep issues, and (4) opportunities for the future. Conclusion: Understanding the current clinical management practices used by oncology HCPs to manage sleep disturbances, along with their perceived opportunities to improve the management of sleep in cancer care is crucial. Efforts to implement these opportunities should focus on co-design with relevant stakeholders at all levels. Trial registration: Registry: ANZCTR.org.au, TRN: ACTRN12622001035718, registration date: July 25, 2022.
- 27 February 2026
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 34 (3) , 257
Open AccessClinical insights into the management of sleep disturbances within cancer care: a qualitative analysis
Purpose: The present study aimed to gain a deeper understanding of how oncology healthcare professionals’ (HCPs) manage sleep disturbances. Methods: Semi-structured interviews were conducted with 10 oncology HCPs (medical oncologists, oncology nurse practitioners, clinical nurse consultants) working in metropolitan Perth, Western Australia. Reflexive thematic analysis was used to understand oncology HCPs’ perspectives on treating sleep disturbances, explore challenges and barriers to their management, as well as opportunities for improvement. Results: Four main themes were developed: (1) sleep disturbances are underreported and underassessed, (2) poor sleep can be difficult to manage, (3) limited capacity to address sleep issues, and (4) opportunities for the future. Conclusion: Understanding the current clinical management practices used by oncology HCPs to manage sleep disturbances, along with their perceived opportunities to improve the management of sleep in cancer care is crucial. Efforts to implement these opportunities should focus on co-design with relevant stakeholders at all levels. Trial registration: Registry: ANZCTR.org.au, TRN: ACTRN12622001035718, registration date: July 25, 2022.
- 3 October 2025
- Published by Elsevier in Lung Cancer
- Vol. 209, 108786
Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer
- 3 October 2025
- Published by Elsevier in Lung Cancer
- Vol. 209, 108786
Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer
- Top Cited PapersOpen Access
- 20 March 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (10) , 1984-1998
Effects of exercise on inflammation in female survivors of nonmetastatic breast cancer: a systematic review and meta-analysis
Background: Despite advances in breast cancer treatment, recurrence remains common and contributes to higher mortality risk. Among the potential mechanisms, inflammation plays a key role in recurrence by promoting tumor progression. Exercise provides a wide array of health benefits and may reduce inflammation, potentially reducing mortality risk. However, the effects of exercise, including mode (ie, resistance training [RT], aerobic training [AT], and combined RT and AT) and program duration, on inflammatory biomarkers in breast cancer survivors remain to be elucidated. Methods: A systematic search was undertaken in PubMed, CINAHL, Embase, SPORTDiscus, and CENTRAL in August 2024. Randomized controlled trials examining the effects of exercise on interleukin-1 beta (IL-1β), interleukin 6 (IL-6), IL-8, IL-10, tumor necrosis factor alpha (TNF-α), and C-reactive protein (CRP) were included. A random-effects meta-analysis was undertaken to quantify the magnitude of change. Results: Twenty-two studies were included (n = 968). Exercise induced small to large statistically significant reductions in IL-6 (standardized mean difference [SMD] = −0.85; 95% CI = −1.68 to −0.02; P = .05) and TNF-α (SMD = −0.40; 95% CI = −0.81 to 0.01; P = .05) and a trend for a decrease in CRP. When stratifying by exercise mode, trends toward reduction in IL-6 and TNF-α were observed for combined exercise, while changes were not generally affected by exercise program duration. Conclusion: Exercise, especially combined RT and AT, can reduce pro-inflammatory biomarkers, and may be a suitable strategy to reduce inflammation in breast cancer survivors. However, further research is needed to investigate the effects of exercise mode and program duration on markers of inflammation in this survivor group.
- 20 March 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (10) , 1984-1998
Top Cited PapersOpen AccessEffects of exercise on inflammation in female survivors of nonmetastatic breast cancer: a systematic review and meta-analysis
Background: Despite advances in breast cancer treatment, recurrence remains common and contributes to higher mortality risk. Among the potential mechanisms, inflammation plays a key role in recurrence by promoting tumor progression. Exercise provides a wide array of health benefits and may reduce inflammation, potentially reducing mortality risk. However, the effects of exercise, including mode (ie, resistance training [RT], aerobic training [AT], and combined RT and AT) and program duration, on inflammatory biomarkers in breast cancer survivors remain to be elucidated. Methods: A systematic search was undertaken in PubMed, CINAHL, Embase, SPORTDiscus, and CENTRAL in August 2024. Randomized controlled trials examining the effects of exercise on interleukin-1 beta (IL-1β), interleukin 6 (IL-6), IL-8, IL-10, tumor necrosis factor alpha (TNF-α), and C-reactive protein (CRP) were included. A random-effects meta-analysis was undertaken to quantify the magnitude of change. Results: Twenty-two studies were included (n = 968). Exercise induced small to large statistically significant reductions in IL-6 (standardized mean difference [SMD] = −0.85; 95% CI = −1.68 to −0.02; P = .05) and TNF-α (SMD = −0.40; 95% CI = −0.81 to 0.01; P = .05) and a trend for a decrease in CRP. When stratifying by exercise mode, trends toward reduction in IL-6 and TNF-α were observed for combined exercise, while changes were not generally affected by exercise program duration. Conclusion: Exercise, especially combined RT and AT, can reduce pro-inflammatory biomarkers, and may be a suitable strategy to reduce inflammation in breast cancer survivors. However, further research is needed to investigate the effects of exercise mode and program duration on markers of inflammation in this survivor group.
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- No. 2
Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastatic Non–Small Cell Lung Cancer: Results From a PD-L1–Unselected Population in the TACTI-002 Study
PURPOSE: Eftilagimod alpha (efti), an antigen-presenting cell (APC) activator, may overcome PD-1/PD-L1 inhibitor primary resistance. This phase II study investigated efti plus pembrolizumab treatment in patients with first-line metastatic non–small cell lung cancer (NSCLC) unselected for PD-L1. METHODS: Patients, naïve to systemic therapy in the metastatic setting, received efti (30 mg subcutaneously every 2 weeks for eight 3-week cycles, then every 3 weeks up to 54 weeks) plus pembrolizumab (200 mg intravenously every 3 weeks for up to 105 weeks). The primary end point was objective response rate (ORR) by immune RECIST. Secondary end points included duration of response (DoR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and tolerability. Exploratory end points included identification and characterization of biomarkers. PD-L1 tumor proportion score (TPS) was assessed centrally. RESULTS: In the intention-to-treat population (n = 114), the median age was 67 years (range, 44-85), 73.7% was male, and 62.3% had an Eastern Cooperative Oncology Group performance status score of 1. Most patients (77.8%) had low/negative (<50%) PD-L1 TPS. The unconfirmed ORR (iRECIST) was 40.4%, leading to a confirmed ORR of 35.1%. The median DoR was 21.6 months, the DCR was 72.8%, and the median PFS (iRECIST) was 6.6 months. The median OS was 20.2 months, with 44.7% patients alive at 24 months. Antitumor activity was seen across all PD-L1 levels. A low proportion of patients had treatment-related adverse events leading to permanent discontinuation (8.8%). CONCLUSION: The APC activator, efti, on top of pembrolizumab was well tolerated and showed encouraging antitumor activity in patients with first-line NSCLC irrespective of tumor PD-L1 expression.
- 1 March 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- No. 2
Eftilagimod Alpha Plus Pembrolizumab in First-Line Metastatic Non–Small Cell Lung Cancer: Results From a PD-L1–Unselected Population in the TACTI-002 Study
PURPOSE: Eftilagimod alpha (efti), an antigen-presenting cell (APC) activator, may overcome PD-1/PD-L1 inhibitor primary resistance. This phase II study investigated efti plus pembrolizumab treatment in patients with first-line metastatic non–small cell lung cancer (NSCLC) unselected for PD-L1. METHODS: Patients, naïve to systemic therapy in the metastatic setting, received efti (30 mg subcutaneously every 2 weeks for eight 3-week cycles, then every 3 weeks up to 54 weeks) plus pembrolizumab (200 mg intravenously every 3 weeks for up to 105 weeks). The primary end point was objective response rate (ORR) by immune RECIST. Secondary end points included duration of response (DoR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and tolerability. Exploratory end points included identification and characterization of biomarkers. PD-L1 tumor proportion score (TPS) was assessed centrally. RESULTS: In the intention-to-treat population (n = 114), the median age was 67 years (range, 44-85), 73.7% was male, and 62.3% had an Eastern Cooperative Oncology Group performance status score of 1. Most patients (77.8%) had low/negative (<50%) PD-L1 TPS. The unconfirmed ORR (iRECIST) was 40.4%, leading to a confirmed ORR of 35.1%. The median DoR was 21.6 months, the DCR was 72.8%, and the median PFS (iRECIST) was 6.6 months. The median OS was 20.2 months, with 44.7% patients alive at 24 months. Antitumor activity was seen across all PD-L1 levels. A low proportion of patients had treatment-related adverse events leading to permanent discontinuation (8.8%). CONCLUSION: The APC activator, efti, on top of pembrolizumab was well tolerated and showed encouraging antitumor activity in patients with first-line NSCLC irrespective of tumor PD-L1 expression.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer
PDF file - 39K, Tumor growth inhibition of patient derived colorectal cancer explant to oxaliplatin.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer
PDF file - 39K, Tumor growth inhibition of patient derived colorectal cancer explant to oxaliplatin.